Congratulation to the Expansion of Medicilon Drug Research and Development Laboratory

On December 4th, with the completion of the last concrete pouring, the expansion project of the drug research and development laboratory of Shanghai Medicilon Inc has been completed.  This marks the further strengthening of Medicilon's one-stop biopharmacetical preclinical R&D service platform capabilities.

Refresh the Progress Again and Continue New Drug R&D

Medicilon Drug R&D Laboratory Expansion Project

From a blueprint to the final construction, every corner and every detail of Medicilon's drug R&D laboratory embodies the quality of ingenuity, which also witnesses the confidence and determination of Medicilon to empower more new drug research and development.  The expansion project was started in early 2022.  Relying on the scientific and rigorous laboratory design scheme and efficient and high-quality construction capabilities, the main structure was successfully capped, the engineering construction were successfully achieved, and also laying a solid foundation for the on-schedule completion of follow-up projects.

The demand for new drug research and development is accelerating, and the expansion project of Medicilon's drug research and development laboratory came into being in the general trend of the development of the times.  After the expansion project is completed, it will comprehensively improve the technical service level of Medicilon in the field of new drug research and development.  At that time, Medicilon will not only be able to provide more R&D services with greater difficulties and higher added value, but also meet the large-scale and continuous drug R&D needs of large pharmaceutical companies.  Medicilon could achieve the efficient coordination of the whole process of new drug R&D, help the global "First in class" and "Best in class" drug innovation, and improve Medicilon's CRO+CDMO innovative research and development capabilities and project undertaking capabilities.

Medicilon Drug Research and Development Laboratory Expansion Project Renderings

The R&D laboratory is the "strong need" for Medicilon's technological innovation, and it is also the "incubation nest" for new drug research and development.  Currently, Medicilon has 81,600 square meters of R&D laboratories, and its services cover the whole process of preclinical new drug research, including drug discovery, pharmaceutical research and preclinical research.  Medicilon has provided new drug research and development services for more than 1,710 clients around the world, and successfully assisted 268 INDs to pass the approval of CFDA/NMPA, US FDA, and Australian TGA to enter clinical trials. (Data from Medicilon’s 2022 semi-annual report)

Dr. Chunlin Chen, Founder and CEO of Medicilon, said, "The drug R&D laboratory expansion project is a key part of Medicilon's strategic layout.  As a one-stop biopharmaceutical preclinical R&D service CRO, Medicilon will give full play to its advantages in biomedical technology development and registration declaration, continue to build a higher-level, deeper, and wider-ranging innovative technology service platform, and empower global partners to help more new drug research and development and innovation."